Back to top
more

Hologic (HOLX)

(Delayed Data from NSDQ)

$68.98 USD

68.98
1,747,081

+1.03 (1.52%)

Updated Aug 13, 2025 04:00 PM ET

After-Market: $69.00 +0.02 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (153 out of 245)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here is What to Know Beyond Why Hologic, Inc. (HOLX) is a Trending Stock

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.

Zacks Equity Research

Here's Why Investors Should Retain ResMed (RMD) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about ResMed (RMD) backed by the continued demand for digital health solutions.

Zacks Equity Research

Teleflex's (TFX) Wattson Temporary Pacing Receives FDA Nod

by Zacks Equity Research

Teleflex's (TFX) Wattson Temporary Pacing Guidewire offers dual functionality, allowing both valve delivery and ventricular bipolar pacing during TAVR or BAV treatments.

Zacks Equity Research

Inari Medical (NARI) Launches New Catheters to Address VTE

by Zacks Equity Research

Inari Medical's (NARI) latest launches are expected to serve a wider patient pool by improving treatment options.

Zacks Equity Research

3 Reasons to Retain Intuitive Surgical (ISRG) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Intuitive Surgical (ISRG) owing to its strength in robotics.

Zacks Equity Research

Here's Why You Should Retain Exact Sciences (EXAS) Stock Now

by Zacks Equity Research

Investors are optimistic about Exact Sciences (EXAS) led by continued strength across the Screening and Precision Oncology businesses.

Zacks Equity Research

Syneos Health (SYNH) Sell-Off Appears Strategic Amid Margin Woes

by Zacks Equity Research

Syneos Health's (SYNH) purchase price represents a 24% premium to its unaffected closing stock price prior to the announcement. Margin pressure continues to weigh on the stock.

Zacks Equity Research

LabCorp (LH) Provides Update on Planned Spinoff of Fortrea

by Zacks Equity Research

After separation from LabCorp (LH), Fortrea is set to operate as a global contract research organization that offers comprehensive drug and medical device development services.

Zacks Equity Research

Neogen (NEOG) Launches Genomic Test for Beef-on-Dairy Calves

by Zacks Equity Research

Neogen's (NEOG) new Igenity BeefXDairy test is an additional tool, enabling producers to gather crucial data they need to advance and grow their operations effectively and sustainably.

Zacks Equity Research

Masimo's (MASI) New FDA Approval to Boost Patient Monitoring

by Zacks Equity Research

Masimo's (MASI) Radius VSM is expected to equip any hospital bed with comprehensive monitoring and offer more personalized care without additional bedside equipment.

Zacks Equity Research

Here's Why Investors Should Retain Thermo Fisher (TMO) Stock

by Zacks Equity Research

Investors continue to be optimistic about Thermo Fisher's (TMO) continued strength across its end markets and the the execution of the growth strategy.

Zacks Equity Research

HealthEquity (HQY) Surpasses Q1 Earnings Estimates, FY24 View Up

by Zacks Equity Research

HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in all its segments, in the first quarter of fiscal 2024.

Zacks Equity Research

Here's Why You Should Hold Integer Holdings (ITGR) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Integer Holdings (ITGR) owing to its improving non-medical sales and a solid foothold in the broader MedTech space.

Zacks Equity Research

Thermo Fisher's (TMO) Unveils Orbitrap Astral Spectrometer

by Zacks Equity Research

Thermo Fisher's (TMO) OrbitrapTM AstralTM mass spectrometer enables accurate and exact quantification in proteomics laboratories.

Zacks Equity Research

Here's Why You Should Invest in IDEXX (IDXX) Right Now

by Zacks Equity Research

Investors continue to be optimistic about IDEXX (IDXX) on the strength of the Companion Animal Group business.

Zacks Equity Research

Hologic (HOLX) Stock Up 5.6% YTD: Will the Rally Continue?

by Zacks Equity Research

The higher capital equipment revenues, procedural volumes return and an acceleration from the new business lines poise Hologic (HOLX) for future growth.

Zacks Equity Research

Here's Why You Should Retain AMN Healthcare (AMN) Stock for Now

by Zacks Equity Research

Investors remain optimistic about AMN Healthcare's (AMN) broad array of services.

Zacks Equity Research

Here's Why You Should Invest in Edward Lifesciences (EW) Now

by Zacks Equity Research

Investors continue to be optimistic about Edward Lifesciences (EW) on the strength of the Surgical Structural Heart business and the Critical Care segment.

Zacks Equity Research

Illumina's (ILMN) New AI Tool to Predict Genomics Disease

by Zacks Equity Research

Illumina's (ILMN) PrimateAI-3D will be made broadly available to the genomics community integrated across Illumina Connected Software.

Zacks Equity Research

Here's Why You Should Retain PacBio (PACB) Stock for Now

by Zacks Equity Research

PacBio's (PACB) product development activities raise optimism about the stock.

Zacks Equity Research

Reasons to Retain Quest Diagnostics (DGX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Quest Diagnostics (DGX) on the strength of the base business performance and its strategies to accelerate growth.

Zacks Equity Research

Hologic (HOLX) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, Hologic (HOLX) closed at $79.15, marking a +0.33% move from the previous day.

Zacks Equity Research

Haemonetics (HAE) Hospital Arm Grows, Plasma Volume Improves

by Zacks Equity Research

Within Haemonetics (HAE) Vascular Closure, growth is led by the opening of new accounts and increasing penetration to gain share in the top U.S. EP hospitals.

Zacks Equity Research

Charles River (CRL) to Build RightSource Lab With New Pact

by Zacks Equity Research

Charles River (CRL) will establish a CGMP testing lab at Wheeler's factory through latest partnership.

Zacks Equity Research

Veeva Systems (VEEV) Beats on Q1 Earnings, Ups FY24 Outlook

by Zacks Equity Research

Veeva Systems' (VEEV) fiscal Q1 results reflect impressive performances by both segments.